J. Goldman & CO LP Roivant Sciences Ltd. Transaction History
J. Goldman & CO LP
- $3.27 Billion
- Q2 2024
A detailed history of J. Goldman & CO LP transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, J. Goldman & CO LP holds 1,307,543 shares of ROIV stock, worth $15.3 Million. This represents 0.42% of its overall portfolio holdings.
Number of Shares
1,307,543Holding current value
$15.3 Million% of portfolio
0.42%Shares
1 transactions
Others Institutions Holding ROIV
# of Institutions
314Shares Held
496MCall Options Held
991KPut Options Held
1.15M-
Sb Investment Advisers (Uk) LTD London, X071.4MShares$834 Million6.97% of portfolio
-
Viking Global Investors LP69.2MShares$808 Million2.91% of portfolio
-
Qvt Financial LP New York, NY66.7MShares$779 Million72.99% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$413 Million0.01% of portfolio
-
Morgan Stanley New York, NY29.3MShares$343 Million0.02% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $8.23B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...